Intravenous (IV) tenecteplase works just as well as IV alteplase in patients with large-vessel occlusion (LVO) stroke who are eligible for thrombolysis, new research shows. In a prespecified secondary ...

New research provides further evidence that thrombolysis benefits select patients with acute ischemic stroke up to 24 hours after symptom onset. In the HOPE trial, administration of intravenous (IV) ...

Comprehensive protocols in emergency departments (EDs) can allow rapid assessment of stroke patients eligible for early-stage treatment, according to a study published in the latest Medical Journal of ...

Biogen has licensed a new drug from Japanese biotech TMS that it hopes could provide a big advance on an old treatment approach – using clot-busting thrombolytic drugs to treat ischaemic stroke. The ...

Vascular imaging (including transcranial Doppler ultrasonography, CT angiography and magnetic resonance angiography) performed before thrombolysis might demonstrate spontaneous reperfusion that would ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Thrombolytic Science, LLC (TSI) today announced initiation of a Phase 2 clinical trial to confirm the efficacy and safety of its sequential dual-treatment regimen of ...

Neurologists around the world are aware that the delivery of thrombolytic treatment for stroke in Helsinki University Hospital, Finland, is freaking fast - but is it too fast? A new study published on ...

The FDA approved tenecteplase (TNKase) for adult stroke patients, Genentech announced on Monday. A clot-dissolving tissue plasminogen activator (tPA), tenecteplase is now indicated for acute ischemic ...

Around 15 years have now elapsed since thrombolysis was first shown to be effective for treating acute ischemic stroke, but therapeutic uptake has been modest. As outlined in this Review, research ...

LOS ANGELES, CA—The outcomes of mechanical thrombectomy in patients with acute ischemic stroke caused by large-vessel occlusions appear similar regardless of whether the procedure is preceded by IV ...

Thrombolytic drugs are the main treatment for stroke, but they have often not been recommended for people who have an aneurysm in their brains that has not ruptured. A new study (“Risk of Aneurysm ...

CAMBRIDGE, Mass., Thrombolytic Science, LLC (TSI) today announced initiation of a Phase 2 clinical trial to confirm the efficacy and safety of its sequential dual-treatment regimen of low-dose tissue ...